Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | FPR1 | P21462 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19475180 | 0.83 | ALDH1A1 (0.37) | ALDH1A1MAPK1TP53LMNAGAA | |
| SCHEMBL15902219 | 0.77 | TLR7 (0.46) | ALDH1A1MAPK1GLATLR7 | |
| SCHEMBL19181354 | 0.67 | MEN1 (0.40) | ALDH1A1LMNAGAAMAPTMEN1 | |
| SCHEMBL1302080 | 0.65 | TLR7 (0.44) | ALDH1A1MAPK1LMNAHPGDGLA | |
| SCHEMBL14758127 | 0.64 | TLR7 (0.47) | ALDH1A1MAPK1GLATLR7 | |
| SCHEMBL6527375 | 0.61 | TP53 (0.66) | MAPK1TP53LMNAGAAMAPT | |
| SCHEMBL10656222 | 0.61 | CYP3A4 (0.40) | ALDH1A1TP53LMNAGAAMAPT | |
| SCHEMBL7481212 | 0.61 | ALDH1A1 (0.42) | ALDH1A1TP53LMNAGAAMAPT | |
| SCHEMBL128 | 0.61 | TLR7 (0.49) | TLR7 | |
| SCHEMBL1301869 | 0.60 | ALDH1A1 (0.39) | ALDH1A1MAPK1TP53LMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190127368-A1 | NLRP3 MODULATORS | IFM THERAPEUTICS INC (US) | 2019-05-02 | — | — | US | disclosed |
| US-20190127368-A1 | NLRP3 MODULATORS | IFM THERAPEUTICS INC (US) | 2019-05-02 | — | — | US | disclosed |
| WO-2017184735-A1 | NLRP3 MODULATORS | IFM THERAPEUTICS, INC (US) | 2017-10-26 | — | — | WO | disclosed |
| WO-2017184735-A1 | NLRP3 MODULATORS | IFM THERAPEUTICS, INC (US) | 2017-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190127368-A1 | NLRP3 MODULATORS | NLRP3, TLR7, TLR8 | ALDH1A1 3322/4885MAPK1 677/4885TP53 100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.